Form 4: Adaptive Biotechnologies CCO Executes Stock Sale
Statement of Changes in Beneficial Ownership
Chief Commercial Officer Susan Bobulsky sold 11,000 shares of Adaptive Biotechnologies common stock via a 10b5-1 plan.
Summary
- Susan Bobulsky, Chief Commercial Officer of MRD at Adaptive Biotechnologies, sold 11,000 shares of common stock.
- The transaction occurred on June 4, 2026, at a price of $18.00 per share.
- Following the sale, the reporting person retains beneficial ownership of 416,775 shares.
- The sale was executed under a pre-established Rule 10b5-1 trading plan adopted on December 16, 2025.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as the sale was pre-planned and represents a small portion of the executive's total holdings.
Positives
- The transaction was conducted under a pre-planned Rule 10b5-1 trading plan, which typically indicates the sale is for personal financial planning rather than a reaction to non-public information.
Negatives
- The sale represents a reduction in the insider's direct equity stake in the company.
Risks
- Insider selling can sometimes be perceived negatively by the market as a signal of management's view on the company's valuation.
Future Outlook
No forward-looking guidance or operational outlook was provided in this filing.
Industry Context
StockSavvy.ai notes that insider sales executed via 10b5-1 plans are standard practice for executives in the biotechnology sector to manage personal liquidity and diversify portfolios without triggering concerns regarding insider trading regulations.
Comparison to Industry Standards
- The use of a 10b5-1 plan is consistent with standard corporate governance practices for executive officers at publicly traded biotech firms.
- The volume of shares sold is relatively small compared to the total remaining holdings of the executive.
Stakeholder Impact
- Minimal impact expected on shareholders as the sale was executed through a pre-arranged plan.
Next Steps
- No future actions or milestones were disclosed in this filing.
Key Dates
| Date | Description |
|---|---|
| 2025-12-16 | Date the Rule 10b5-1 trading plan was adopted. |
| 2026-06-04 | Date of the stock sale transaction. |
| 2026-06-08 | Date the Form 4 was signed and filed. |
Keywords
Adaptive Biotechnologies, ADPT, Insider Trading, Form 4, SEC, Biotech
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.